Skip to main content

Fexapotide triflutate FDA Approval Status

FDA Approved: No
Generic name: fexapotide triflutate
Previous Name: NX-1207
Company: Nymox Pharmaceutical Corporation
Treatment for: Benign Prostatic Hyperplasia

Fexapotide triflutate is an injectable pro-apoptotic agent in development for the treatment of benign prostatic hyperplasia.

Development timeline for fexapotide triflutate

Mar  3, 2022Nymox Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
Feb  5, 2018Nymox Announces US NDA for Fexapotide for BPH
Jan 30, 2018Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.